Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013734B2 · kind B2 · utility
0Cited by
31References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 2019 |
| Grant date | May 25, 2021 |
| Priority date | — |
| Expiry date | Jul 30, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.